¡°	PVA base mbc	18.321988697616074
	PVA effectiveness	16.736607586594214
¡°	PVA mbc technical drawback	14.731665070515216
¡°	PVA MBC	12.589217366637424
	PVA moisture barrier coating	9.786105889106912
	argument	8.143327444933051
	Opadry AMB formulation	7.58907030885582
	infringement allegation	6.111649519579098
	conjugate estrogen tablet	5.5866026321014415
	Colorcon PCT description	4.958350417500875
	Colorcon PCT disclosure	4.958332131265631
	hormone replacement therapy product	4.230414651847904
	conjugate estrogen pharmaceutical composition	4.157996328647299
	powder conjugate estrogen composition	3.327162019081448
	moisture degradation	2.468150892261684
	propose generic product	2.1465003523087667
	moisture tight[ness	1.8694422718663397
	Abbreviated New Drug Application	1.792361658866499
	moisture barrier coating comprising ethylcellulose limitation	1.6038420667857884
	Manufacturing Chemist	1.5897838764199934
	peri menopausal	1.5623403179827005
	moisture tight tablet	1.2405570673228257
	polyvinyl alcohol	1.2301123801328364
	highly effective moisture barrier formulation	1.188550356226737
	post menopausal disorder	0.9076339732710265
	Groppenbacher	0.8785123048312827
	inorganic excipient	0.8390156968073151
	coat tablet	0.4589171837191169
	invoice	0.33806685960214783
	pharmaceutical tablet	0.3321494386952667
	Patent Cooperation Treaty	0.23582684068096274
	hormonal treatment	0.22650445730273008
	gastrointestinal tract	0.18442017948892728
	storage relate degradation	0.1709694215863481
	one organic excipient	0.16045800376213198
	absorption	0.1594808220557528
	international application	0.15541294394903346
	scientific conference	0.1352597002126356
	several technical drawback	0.12351265526215242
	pharmaceutical formulation	0.11959809167860462
	distribution	0.05442327223226761
	marketing	0.04220593555116709
	oral administration	0.023937917908048847
	Prior Art	0.02266830481321243
	prosecution history estoppel	0.021278411682106174
	J.A.	0.020970370122271414
	solid unit dosage form	0.020783234242190612
	Lourie	0.014879292068210134
	noninfringement	0.01452111302106396
	New York	0.014104205526768212
	serious question	0.013420947665437005
	three scientific article	0.01263909322171193
	presumption	0.011679484781082747
	Southern District	0.011225288962250118
	ANDA	0.010219725340622194
	generic version	0.009981569419287427
	equivalent	0.00919500075250799
	inter alia	0.0068526060629830144
	several pre amendment reference	0.005492149601639159
	field	0.005043442659452385
	patentee narrow amendment	0.004760081959514134
	May	0.002627848235051513
	September	0.0023804375578220837
	November	0.0022674294013690257
	weight	0.0019526582959853984
	July	0.0016022954293696582
	sale	0.0015225174595286221
	January	0.0012514184089547564
	March	0.0011910430304065073
	original amend scope	0.0007664917040659498
	original independent	0.0004799409539715808
	patentability	0.00045972555400710486
	en banc	0.00019261440199150163
	summary judgment de novo	0.00016834433242084718
	holding	0.00011560846636650117
	background	0.00011254528070553086
	several fact	5.5710029478053963e-05
	examiner	5.3086506721035215e-05
	jurisdiction	4.773067996246011e-05
	suit	2.41155665428788e-05
	emphasis	1.935723882128128e-05
	Claim	1.795767197037392e-05
	standard	1.3926403323652298e-05
	time	5.141282400086078e-06
	Idaho	4.0487833017541e-06
	district court grant	8.456805203683853e-07
	assert	7.36497374941636e-07
	action	1.7079505169022056e-07
	use	1.5996186595581456e-08
	U.S.	1.1574564376142253e-09
	Court	0.0
	Appeals	0.0
	Inc.	0.0
